99 Respiratory Syncytial Virus (RSV) Prophylaxis for Infants Discharged from Tertiary Care Settings: Compliance and Outcomes
Bibliographic record
Abstract
RSV prophylaxis with palivizumab is initiated in some tertiary care centres prior to discharge. In the 1999–2000 RSV season, an audit at one of three affiliated Canadian centres revealed that after babies were discharged, up to 30% of parents were not aware of prophylaxis being continued. In order to facilitate compliance, an enhanced educational program was implemented and an evaluative study conducted. 1) To assess the compliance with RSV prophylaxis after infants have been discharged from hospital; 2) To assess outcomes due to RSV-related admissions and potential adverse events temporally associated with palivizumab prophylaxis. The study targeted infants whose RSV prophylaxis was started at 3 affiliated tertiary care centres during the RSV season from 11/2000 to 3/2001. Prophylaxis was based on Canadian guidelines and was accompanied by an educational program for health care providers and parents. Telephone survey data were supplemented by reviews of the Hospital Medical records, as indicated. Data were obtained on 292 subjects, representing 71.4% of those eligible for prophylaxis. Mean gestational age 29.0 wks (SD±2.66); mean birth weight 1293 grams (SD±457); male:female ratio 1.2:1. RSV prophylaxis was continued in the community in 81.7% of subjects, no pro-phylaxis given in 10.6% and the prophylaxis status undetermined in 7.7%. Symptoms of respiratory viral infections (RVI) resulting in medical visits occurred in 16.1% (47/292). 7.9% (23/292) had at least 1 admission, with the reason being RVI in 4.8% (14/292). There was 1 proven RSV-related admission (0.34%). The frequency of potential adverse events regardless of causation were: fever 2.7%, rash 2.1%, vomiting 1.4%, irritability <1%, and injection site reactions <1%. Following initiation of prophylaxis accompanied by an enhanced educational package, compliance with continued RSV prophylaxis was high. The low rates of admissions related to RSV and potential adverse events are consistent with favorable safety and effectiveness profiles of palivizumab.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.010 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".